Ipsen · 4 hours ago
Vice President & Head of Rare Disease Global Partnering
Ipsen is a global biopharmaceutical group focused on innovation and specialty care. The Vice President, Head of Rare Disease Global Partnering is responsible for establishing a strong Rare Disease pipeline through business development activities, including due diligence and negotiation of transactions aligned with corporate strategy.
BiotechnologyPharmaceuticalProduct Research
Responsibilities
Manage due diligence, structure and negotiate transactions, including in/out- licensing deals, product acquisitions, strategic partnerships, and M&A in Rare Disease, focused on assets that will enhance the company’s portfolio
Collaborate with EVP, Chief Business Officer and stakeholder functions (including but not limited to C-level roles, country/regional leadership, Commercial Franchises, R&D, IP, Finance, Legal, Manufacturing and Corporate Strategy) to establish business development strategy & goals for Rare Disease that are aligned with overall business/corporate strategy and objectives
Ensure high-quality due diligence
Execute value-add deals
Lead contract negotiations and work with stakeholder functions to ensure high-quality contracts are negotiated and executed to protect future interests of Ipsen’s business
Contribute to the strategic direction of corporate business development through analysis of evolving market and R&D/competitive landscape in Rare Disease and provide concise and accurate updates and documentation to senior management (and committees involving members from the Board of Directors when necessary) for deal review and decision-making
Contribute to the strategic direction of Rare Disease Franchise defining and steering Ipsen Rare Disease strategy
Deliver accurate and timely updates, and provide customized support to the Executive Vice President, Chief Business Officer for regular review and decision making at senior management level
Maintain professional relationships with potential strategic partners and network with external companies and advisers in the industry including regular attendance at appropriate conferences and other industry events
Qualification
Required
Master's degree in Science required
Minimum of 12-15 years industry experience from a global top biotech or medium-sized pharma company
Broad experience of business development in the R&D and commercial oncology context
Substantial deal sheet, including in- and out-licensing, M&A, product acquisitions/divestments, and strategic partnerships in the oncology space
Strong business and strategic acumen
Experienced at structuring associated with biopharma deal making
Ability to manage complex deals and perform solid market, company and product analysis and due diligence
Proven project management and workflow delegation skills
Good awareness of the biopharma ecosystem, including the deal-making landscape
Track record of successfully securing deals in Rare Disease as a lead negotiator
Excellent relationship and networking skills
Well-established network in the pharma industry, particularly in the oncology space
Experience with leading a team
Fluent English
French is a plus
Preferred
Advanced post-graduate degrees including Masters, Ph.D. in Chemistry, Biology or Medicine ideal
Master's in Finance or MBA desirable
International experience outside the US
Sensitivity to (and familiarity with) the European and French business culture is an advantage
Company
Ipsen
Ipsen is a global specialty-driven biopharmaceutical company focused on innovation and specialty care.
H1B Sponsorship
Ipsen has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (1)
2020 (1)
Funding
Current Stage
Public CompanyTotal Funding
$574.72M2025-03-19Post Ipo Debt· $545.59M
2017-11-20Post Ipo Equity· $29.13M
2005-12-16IPO
Leadership Team
Recent News
2026-01-17
Pharma Letter
2026-01-16
Company data provided by crunchbase